Related Experiment Video
Updated: Feb 20, 2026

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
Effectiveness of bivalent BA.1 mRNA booster vaccines during the autumn 2022 COVID-19 booster programme in adults aged
Paul Madley-Dowd1, Elsie M F Horne2, William J Hulme3
1Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK; Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.
Objective:
Estimate the effectiveness and comparative effectiveness of booster vaccination with bivalent original/omicron BA.1 mRNA-1273 (Moderna) and original/omicron BA.1 BNT162b2 (Pfizer-BioNTech) against COVID-19 hospitalisation and death in adults aged ≥50 years.
Design:
Matched cohort studies emulating target trials.
Setting:
With approval of NHS England, we analysed linked primary care, hospital, and COVID-19 surveillance records available within the OpenSAFELY-TPP research platform.
Participants:
For comparison of boosting with no boosting, 3,464,877 adults eligible for booster vaccination during the autumn 2022 UK COVID-19 vaccine rollout, registered with a general practice using the TPP SystmOne clinical information system in England. For the between-vaccine comparison 531,129 boosted pairs.
Interventions:
Vaccination with bivalent BA.1 mRNA-1273 or BNT162b2.
Main Outcome Measures:
COVID-19-related hospital admission or death, non-COVID-19 death, fracture (negative control outcome).
Results:
In approximately 2.5-million person-years follow up there were 14,436 COVID-19-related hospital admissions, 1152 COVID-19-related deaths, 32,184 non-COVID-19 deaths, and 52,758 fractures. The 350-day risks/1000 of COVID-19 hospitalisation and COVID-19 death were 3.78 (95% CI 3.65-3.91) and 0.29 (0.26, 0.33) respectively after boosting and 6.81 (6.65-6.98) and 0.61 (0.56, 0.66) without boosting. Over 350 days' follow-up, adjusted hazard ratios were: COVID-19 hospitalisation 0.51 (95% CI 0.50, 0.53); COVID-19 death 0.45 (0.40, 0.51); non-COVID-19 death 0.56 (0.55, 0.58) and fracture 0.89 (0.87, 0.91). Booster effectiveness waned over time, with greatest effectiveness in the first 70 days after vaccination. The 350-day risks of COVID-19 hospitalisation, COVID-19 death and fracture were similar for the two vaccine brands but higher in the bivalent mRNA-1273 group for non-COVID-19 death (risk difference per 1000 0.88 [0.35, 1.40]).
Conclusions:
Rates of COVID-19-related hospitalisation and death were substantially lower after bivalent original/omicron BA.1 mRNA booster vaccine than in people who remained unboosted. Apparent protection against fracture suggests some unmeasured confounding. Outcomes appeared similar for the Moderna and Pfizer-BioNTech vaccines.
More Related Videos
Related Concept Videos
Vaccinations
Bioequivalence studies: Biowaivers
Antimicrobial Effectiveness
Bioavailability Study Design: Healthy Subjects Versus Patients
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Bioavailability Study Design: Single Versus Multiple Dose Studies

